Brief: Vaccinex Reports First Quarter 2020 Financial Results And Provides Corporate Update
14/05/2020 13:50
Vaccinex Inc VCNX.O :
* VACCINEX REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND
PROVIDES CORPORATE UPDATE
* VACCINEX INC - CASH AND CASH EQUIVALENTS AND MARKETABLE
SECURITIES ON MARCH 31, 2020 WERE $2.5 MILLION
* VACCINEX INC - ADVANCING PLANS TO EXPAND PEPINEMAB
DEVELOPMENT
TO INCLUDE ALZHEIMER'S DISEASE
* VACCINEX INC - APPROACHING KEY TOPLINE DATA IN NON-SMALL
CELL
LUNG CANCER AND HUNTINGTON'S DISEASE
Source text for Eikon: ID:nGNX3Yfmj2
Further company coverage: VCNX.O
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease